2021-11-15T22:15:18-06:00 2020-12-31 870343246 SQUIRE & COMPANY PC 215 S STATE ST STE 850 SALT LAKE CITY UT 841112380 990 2020-01-01 455354811 CROWDCARE FOUNDATION CROW 8007091113 PO BOX 1286 DRAPER UT 84020 JENNIFER AHLSTROM PRESIDENT 8019491034 2021-11-11 true JENNIFER AHLSTROM 999009999 GREGORY O HYDE CPA P00641196 8015330409 2021-11-15 2020 2022-09-23 18:48:47Z X HEALTHTREE FOUNDATION JENNIFER AHLSTROM PO BOX 1286 DRAPER UT 84020 4250766 false X WWW.HEALTHTREE.ORG X 2012 DE PROVIDING PATIENT-CENTERED TOOLS, EDUCATION, AND SUPPORT TO THOSE WITH RARE DISEASES USING A PATIENT-INITIATED DATA PLATFORM IN COLLABORATION WITH DISEASE EXPERTS TO IMPROVE OUTCOMES AND ACCELERATE CURES. 5 4 38 140 0 2860475 3711805 2000 0 -51336 495882 2809139 4209687 127099 124148 0 1079771 1599771 0 68679 971997 1592059 2178867 3315978 630272 893709 952796 2281711 10782 233551 942014 2048160 X PROVIDING PATIENT-CENTERED TOOLS, EDUCATION, AND SUPPORT TO THOSE WITH RARE DISEASES USING A PATIENT-INITIATED DATA PLATFORM IN COLLABORATION WITH DISEASE EXPERTS TO IMPROVE OUTCOMES AND ACCELERATE CURES. false false 1166547 2000 PATIENT ADVOCACY (PSA): WITH A PATIENT'S PERSPECTIVE THE CROWDCARE FOUNDATION PROVIDES PATIENT EDUCATION, MENTORING, PEER-TO-PEER ONLINE COMMUNICATION PLATFORMS AND UPDATED NEWS AND INFORMATION FOR EACH DISEASE COMMUNITY. 147339 124148 SUPPORT FOR CLINICAL TRIALS (SCT): THE CROWDCARE FOUNDATION RECOGNIZES THAT LITTLE-KNOWN DISEASES PROVIDE A SIGNIFICANT CHALLENGE: THERE AREN'T THAT MANY PATIENTS TO PARTICIPATE IN CLINICAL RESEARCH. THE CROWDCARE FOUNDATION AIMS TO PROMOTE CLINICAL TRIAL PARTICIPATION TO HELP ACCELERATE THE PACE OF MEDICAL RESEARCH. THE MYELOMA CROWD RADIO AND ALS CROWD RADIO SHOWS INTERVIEW TOP RESEARCHERS AND ENCOURAGE PATIENTS TO JOIN CLINICAL TRIALS IN THEIR RESPECTIVE DISEASE STATES. THESE SHOWS GIVE PATIENTS INSIGHT INTO THE LATEST RESEARCH BEING PERFORMED. ADDITIONALLY, THE MYELOMA CROWD RESEARCH INITIATIVE (MCRI) IS A CROWDSOURCED AND CROWDFUNDING RESEARCH PROJECT TO FIND AND FUND THE BEST RESEARCH FOR HIGH-RISK MYELOMA PATIENTS. THE MCRI IS NOW FUNDING THREE IMMUNOTHERAPY PROJECTS: DR. DAVID CHUNG AT THE MEMORIAL SLOAN KETTERING CANCER CENTER, DR. CESAR RODRIGUES AT WAKE FOREST UNIVERSITY, AND DR. FRANK ZHAN AT THE UNIVERSITY OF IOWA. ALS CROWD IS DEVELOPING A DATA AGGREGATE SYSTEM FOR ALS PATIENTS TO IDENTIFY KEY DRIVERS AND BIOMARKERS TO BETTER DEFINE THE DISEASE. 1625484 DATA SOLUTIONS (DS): HEALTHTREE IS A PATIENT-INITIATED, RESEARCHER VALIDATED DATA PLATFORM THAT SERVES AS A DATA RESOURCE FOR RESEARCH BUT ALSO PROVIDES BENEFITS BACK TO PATIENTS. HEALTHTREE IS A SHARED-DECISION MAKING TOOL FOR PATIENTS AND HELPS PATIENTS UNDERSTAND THEIR TREATMENT OPTIONS, FIND CLINICAL TRIALS, CONNECT WITH OTHERS WITH SIMILAR DISEASE, AND BECOME EDUCATED ON THEIR DISEASE. 2939370 true true false false false false false false false false true false false false true false true false false false true true false false true false false true false true false false false false false false true false false false false false false false false false false true 15 0 38 true false false false false false false false false false false false false false false X 5 4 false false false false false false false true true false false true true true true false false true false false X JENNIFER AHLSTROM 8019491034 3315 MAYFLOWER AVE SUITE 2 LEHI UT 84043 JENNIFER AHLSTROM PRESIDENT 60.00 X X 126083 0 0 SETH CHRISTENSEN BOARD MEMBER 8.00 X 0 0 0 OWEN LEGARE BOARD MEMBER 5.00 X 0 0 0 DALE SANDERS BOARD MEMBER 1.00 X 0 0 0 ADAM BLUM BOARD MEMBER 2.00 X 0 0 0 ALLYSE SHUMWAY SECRETARY TR 40.00 X 30052 0 0 TODD FOSTER HT PRODUCT M 40.00 X 171308 0 23069 GREGOR BROZEIT ROUNDTABLE D 40.00 X 203286 0 22736 LORA JENSEN SCRETARY/TRE 60.00 X 36854 0 0 JUAN PABLO CAPDEVILA PONCE DE LEON CTO 40.00 X 120191 0 7491 687774 53296 4 false true false X 84939 166200 3460666 3711805 PROGRAM SERVICE REVENUE 812900 2000 2000 2000 84939 41079 -41079 MYELOMA CD QUAL SPONSRSHP INC 812900 536961 536961 536961 4209687 2000 536961 X 113030 113030 11118 11118 193089 126083 36954 30052 1199928 1170969 29639 -680 106876 106876 99878 92550 5029 2299 48950 16890 32060 65206 65206 513167 513167 175767 175767 260544 157052 103492 275808 275808 24668 24184 484 46592 46592 76689 76221 468 1252 1252 1855 1855 16769 15092 1677 OPERATIONAL EXPENSES 29141 29141 FUNDRAISING - GENERAL 17357 17357 FITNESS CHALLENGE 13339 13339 DUES AND SUB (DATA SOL) 10000 10000 14955 7971 1140 5844 3315978 2939370 307929 68679 940645 2027221 100000 144193 27242 16945 12151 10297 952796 2281711 10782 35241 198310 10782 233551 X 942014 1071564 976596 942014 2048160 952796 2281711 X 893709 212437 X X false true X false false X 636693 982751 1231200 2860475 3711805 9422924 636693 982751 1231200 2860475 3711805 9422924 4952408 4470516 536961 536961 9959885 100965 0.44890 0.39510 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 22755 16945 5810 4487 4487 10297 DEFERRED REVENUE 141000 OTHER LIABILITIES 40000 PAYROLL LIABILITIES 17310 198310 4249704 40017 40017 4209687 4209687 3355995 40017 40017 3315978 3315978 SCHEDULE D, PAGE 4, PART XI, LINE 2D RECLASS OF EXPENSES ORIGINALLY INCLUDED IN REVENUE -1,062 FUNDRAISING EVENT EXPENSES 41,079 SCHEDULE D, PAGE 4, PART XII, LINE 2D RECLASS OF EXPENSES ORIGINALLY INCLUDED IN REVENUE -1,062 FUNDRAISING EVENT EXPENSES 41,079 true EUROPE COVID-19 RESEARCH 11118 CHECK 1 false false false false false false SCHEDULE F, PAGE 1, PART I, LINE 2 THE GRANT WAS PROVIDED TO ASSIST WITH MYELOMA RESEARCH BY THE UNIVERSITY OF UTAH HUNSTMAN CANCER INSTITUTE. PEPTIDES AND ELEPHANTS IS A FACILITY THAT HELPED MANUFACTURE PEPTIDES FOR RESEARCH. IT WAS USED TO PURCHASE A PRODUCT THAT THE HUNTSMAN CANCER INSTITUTE INVESTIGATOR USED FOR A COVID STUDY. PRODUCT WAS RECEIVED BY THE HUNTSMAN CANCER INSTITUTE, AND THUS NO OTHER MONITORING WAS NECESSARY. MUSCLES FOR MYE 84939 84939 41079 84939 84939 41079 41079 -41079 true WAKE FOREST UNIVERSTIY 1 MEDICAL CENTER BLVD WINSTONSALEM NC 27157 223849199 501C3 50000 MYELOMA RESEARCH UNIVERSITY OF UTAH 500 HUNTSMAN WAY SALT LAKE CITY UT 84108 870541293 501C3 10000 MYELOMA RESEARCH OHIO STATE UNIVERSITY 14 EAST 15TH AVE COLUMBUS OH 43210 316025986 501C3 13030 MYELOMA RESEARCH UNIVERSITY OF ARKANSAS 4301 WEST MARKHAM STREET LOT 716 LITTLE ROCK AR 72205 716056774 501C3 40000 MYELOMA RESEARCH 4 X X X false false false false false false false false false TODD FOSTER HT PRODUCT MANAGER 170153 1155 23069 194377 GREGOR BROZEIT ROUNDTABLE DIRECTOR 203286 22736 226022 ALTA SCOUT 35%CNTLD ENTITY 98000 RECRUITING SERVICES false FORM 990, PAGE 2, PART III, LINE 4B SUPPORT FOR CLINICAL TRIALS (SCT): THE CROWDCARE FOUNDATION RECOGNIZES THAT LITTLE-KNOWN DISEASES PROVIDE A SIGNIFICANT CHALLENGE: THERE AREN'T THAT MANY PATIENTS TO PARTICIPATE IN CLINICAL RESEARCH. THE CROWDCARE FOUNDATION AIMS TO PROMOTE CLINICAL TRIAL PARTICIPATION TO HELP ACCELERATE THE PACE OF MEDICAL RESEARCH. THE MYELOMA CROWD RADIO AND ALS CROWD RADIO SHOWS INTERVIEW TOP RESEARCHERS AND ENCOURAGE PATIENTS TO JOIN CLINICAL TRIALS IN THEIR RESPECTIVE DISEASE STATES. THESE SHOWS GIVE PATIENTS INSIGHT INTO THE LATEST RESEARCH BEING PERFORMED. ADDITIONALLY, THE MYELOMA CROWD RESEARCH INITIATIVE (MCRI) IS A CROWDSOURCED AND CROWDFUNDING RESEARCH PROJECT TO FIND AND FUND THE BEST RESEARCH FOR HIGH-RISK MYELOMA PATIENTS. THE MCRI IS NOW FUNDING THREE IMMUNOTHERAPY PROJECTS: DR. DAVID CHUNG AT THE MEMORIAL SLOAN KETTERING CANCER CENTER, DR. CESAR RODRIGUES AT WAKE FOREST UNIVERSITY, AND DR. FRANK ZHAN AT THE UNIVERSITY OF IOWA. ALS CROWD IS DEVELOPING A DATA AGGREGATE SYSTEM FOR ALS PATIENTS TO IDENTIFY KEY DRIVERS AND BIOMARKERS TO BETTER DEFINE THE DISEASE. FORM 990, PAGE 6, PART VI, LINE 11B A COPY OF THE RETURN IS PROVIDED TO BOARD MEMBERS VIA EMAIL. FORM 990, PAGE 6, PART VI, LINE 12C COVERED ANNUALLY VIA BOARD MEETINGS. FORM 990, PAGE 6, PART VI, LINE 15A THE COMPENSATION COMMITTEE FOLLOWS THE REBUTTABLE PRESUMPTION OF REASONABLENESS PROCEDURE DESCRIBED IN IRS REGULATIONS SECTION 53.4958-6(C) WHEN SETTING COMPENSATION FOR THE POSITION OF PRESIDENT/CEO AND UTILIZES COMPARABLE NON-PROFIT SALARY DATA FOR ESTABLISHING COMPENSATION LEVELS. FORM 990, PAGE 6, PART VI, LINE 19 CROWDCARE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, OR FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART VIII PART VIII, LINE 8C - THE NET LOSS FROM FUNDRAISING EVENTS REPORTED ON LINE 8C DOES NOT INCORPORATE THE CONTRIBUTION REVENUE FROM ALL FUNDRAISER GROSS RECEIPTS. THE CONTRIBUTION REVENUE IS REPORTED ON LINE 1C AND ON LINE 8A. THE NET ECONOMIC OUTCOME OF CROWDCARE FOUNDATION'S 2020 FUNDRAISERS: GROSS RECEIPTS FROM EVENTS 84,939 LESS: CASH EXPENSES OF EVENTS (41,079) NET ECONOMIC BENEFIT FROM FUNDRAISERS 43,860 SCH B INCLUDES 230,000 OF PLEDGES THAT WERE INCLUDED IN 2019 PLEDGES RECEIVABLE BALANCE. THIS AMOUNT IS NOT INCLUDED IN PART VIII LINE 1F BUT IS INCLUDED IN THE ORGANIZATION'S 481(A) ADJUSTMENT AS "INCOME ACCRUED BUT NOT RECEIVED" ON FORM 3115, SCHEDULE A, PART I, LINE 2A. SANOFI 180,000 KARYOPHARM 50,000 TOTAL 230,000 FORM 990, PART IX, LINE 11G HEALTHTREE AND HTU PROF FEES 483,864 0 0 PROFESSIONAL FEES-RESEARCH FU 468 0 0 PROFESSIONAL FEES-PATIENT ED 4,368 0 0 PAYROLL FEES 24,467 0 0 TOTAL 513,167 0 0 FORM 990, PART XI, LINE 9 SECTION 481(A) ADJUSTMENT-FORM 3115 212,911 ACCRUED TAXES NOT INCLUDED IN 481(A) ADJUSTMENT -474 TOTAL 212,437 FORM 990, PAGE 12, PART XII, LINE 1 ORGANIZATION CHANGED FROM THE CASH TO ACCRUAL METHOD OF ACCOUNTING. SEE FORM 3115.